ReviewViruses2014
Integration site and clonal expansion in human chronic retroviral infection and gene therapy.
Review in Viruses, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.Military Medical Research · 2023Review
- Genome editing of immune cells using CRISPR/Cas9.BMB reports · 2021Review
- Gene Therapy Options as New Treatment for Inherited Peripheral Neuropathy.Experimental neurobiology · 2020Review
- Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Molecular biology of human T cell leukemia virus.Seminars in diagnostic pathology · 2020Review
- HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.Viruses · 2016Review
- Historical review of the causes of cancer.World journal of clinical oncology · 2016Review
- The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.The Journal of clinical investigation · 2016Review
- Retroviral integration: Site matters: Mechanisms and consequences of retroviral integration site selection.BioEssays : news and reviews in molecular, cellular and developmental biology · 2015Review
- HIV-infected cells are frequently clonally expanded after prolonged antiretroviral therapy: implications for HIV persistence.Journal of virus eradication · 2015Review
- Multifunctional facets of retrovirus integrase.World journal of biological chemistry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Retroviral vectors have been successfully used therapeutically to restore expression of genes in a range of single-gene diseases, including several primary immunodeficiency disorders. Although clinical trials have shown remarkable results, there have also been a number of severe adverse events involving malignant outgrowth of a transformed clonal population. This clonal expansion is influenced by the integration site profile of the viral integrase, the transgene expressed, and the effect of the viral promoters on the neighbouring host genome. Infection with the pathogenic human retrovirus HTLV-1 also causes clonal expansion of cells containing an integrated HTLV-1 provirus. Although the majority of HTLV-1-infected people remain asymptomatic, up to 5% develop an aggressive T cell malignancy. In this review we discuss recent findings on the role of the genomic integration site in determining the clonality and the potential for malignant transformation of cells carrying integrated HTLV-1 or gene therapy vectors, and how these results have contributed to the understanding of HTLV-1 pathogenesis and to improvements in gene therapy vector safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.